I-Corps: Automated, noninvasive critical congenital heart disease (CCHD) screening algorithm/software

美国每年有近400万婴儿出生。所有美国新生儿，以及大多数国际新生儿，均使用脉搏血氧仪进行基于血氧饱和度（SpO 2）的危重先天性心脏病（CCHD）筛查。然而，这种筛查仍然错过了美国每年数百名患有危及生命的心脏缺陷的婴儿。拟议中的NeoPOSE技术可以防止与婴儿心脏缺陷晚期检测相关的死亡。此外，它的非侵入性方法和自动解释使其易于使用，以减少与CCHD筛查相关的护理时间。大多数美国州（80%）要求向公共卫生部门报告CCHD筛查数据。大多数卫生保健机构手动提交数据，这是劳动密集型的，容易出错。即使是那些具有自动报告功能的公司，也存在劳动密集型的数据管理困难。NeoPOSE将简化数据传输过程，同时提高其准确性，从而减少与数据管理相关的人工劳动，并提供更可靠的数据，以指导未来的CCHD筛查研究和质量改进。这个I-Corps项目探索了无创血流测量技术的商业潜力，以提高对严重先天性心脏病（CCHD）的及时检测。在其当前形式中，血氧饱和度（SpO 2）血流测量不能用于临床。拟议的NeoPOSE技术采用现成但未使用的无创脉搏血氧测定数据，并使其具有临床相关性。除了CCHD的检测，拟议的技术可能有助于许多其他异常血流的医学疾病（即动脉粥样硬化或血管移植监测）。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

There are nearly 4 million babies born in the US every year. All US newborns, and most internationally, undergo oxygen saturation (SpO2) based Critical Congenital Heart Defects (CCHD) screening with pulse oximeters. However, this screening still misses hundreds of babies with life-threatening heart defects in the US every year. The proposed NeoPOSE technology could prevent deaths associated with late detection of heart defects in babies. Moreover, its noninvasive approach and automated interpretation make it easy to use to reduce nursing time associated with CCHD screening. Most US states (80%) require reporting of the CCHD screening data to public health departments. Most health care facilities submit data manually, which is labor intensive and error prone. Even those with automated reporting have data management difficulties that are labor intensive. NeoPOSE will ease the data transmission process while improving its accuracy, thus decreasing manual labor associated with data management and also providing more reliable data to guide future CCHD screening research and quality improvements. This I-Corps project explores the commercial potential of noninvasive blood flow measurement technology for improved timely detection of Critical Congenital Heart Defects (CCHD). In their current form, oxygen saturation (SpO2) blood flow measurements cannot be used clinically for this purpose. The proposed NeoPOSE technology takes readily available, yet unused, noninvasive pulse oximetry data and makes them clinically relevant. In addition to detection of CCHD, the proposed technology may be helpful for a number of other medical diseases with abnormal blood flow (i.e. atherosclerosis or blood vessel graft monitoring).This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.